Abstract： Objective： To observe the curative effect of modified Datusizi yin combined with glucocorticoid for immunologic thrombocytopenic purpura (ITP). Methods：A total of 120 cases of ITP patients were selected and divided into the control group and the study group according to the random number table method，60 cases in each group. The control group was given glucocorticoid sequential therapy，and the study group was additionally treated with modified Datusizi yin based on the treatment of the control group. The clinical effect and the incidence of adverse reactions were observed and recorded in the two groups. Before and after treatment，the differences in platelet counts as well as the contents of PAIgA， PAIgM，PAIgG，T lymphocyte subsets and related inflammatory factors in serum were compared between the two groups. Results：After treatment，the levels of interleukin-2 (IL-2)，IL-2/IL-4，CD8+，GPⅡb/Ⅲa，GPⅠb/Ⅳ，PAIgA，PAIgM and PAIgG in the two groups were decreased when compared with those before treatment(P＜0.05)，and the above indexes after treatment in the study group were lower than those in the control group(P＜0.05). The levels of IL-4，CD3+，CD4+，CD4+/ CD8 + and platelet in the two groups were increased when compared with those before treatment(P＜0.05)，and the above indexes after treatment in the study group were higher than those in the control group(P＜0.05). The total effective rate was 91.67% in the study group，higher than that of 78.33% in the control group(P＜0.05). The total incidence of adverse reactions was 8.33% in the study group， lower than that of 21.67% in the control group(P＜0.05). After active and symptomatic treatments， the adverse reactions in the two groups were relieved. Conclusion： The therapy of modified Datusizi yin combined with glucocorticoid for ITP can effectively reduce platelet-related antibodies and improve immune function，which has defined clinical effect on Th1/Th2 immune imbalance induced by the activation of various cell signals，and safety.